Formation of Human IFN-β Complex with the Soluble Type I Interferon Receptor IFNAR-2 Leads to Enhanced IFN Stability, Pharmacokinetics, and Antitumor Activity in Xenografted SCID Mice

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Interferon & Cytokine Research

• Publication date

  2004-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/107999004322813363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiviral activities of the soluble extracellular domains of type I interferon receptors

  2001cited by this paper
• The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties.

  2001cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Recombinant human growth hormone-binding protein fails to enhance the in vivo bioactivity of human growth hormone in normal rats.

  1997cited by this paper
• Interferon-β Induces S Phase Accumulation Selectively in Human Transformed Cells

  1997cited by this paper
• Contributions of cloned type I interferon receptor subunits to differential ligand binding 1

  1997cited by this paper
• The neglected role of type I interferon in the T-cell response: implications for its clinical use.

  1996cited by this paper
• Soluble and membrane‐anchored forms of the human IFN‐α/β receptor

  1995cited by this paper
• Mutant U5A cells are complemented by an interferon‐alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster.

  1995cited by this paper
• Cloning and Expression of a Long Form of the β Subunit of the Interferon αβ Receptor That Is Required for Signaling (*)

  1995cited by this paper
• Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*)

  1995cited by this paper
• The human interferon alpha/beta receptor: characterization and molecular cloning.

  1994cited by this paper
• The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction

  1993cited by this paper
• Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

  1992cited by this paper
• The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.

  1992cited by this paper
• Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.

  1992cited by this paper
• Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor.

  1992cited by this paper
• Soluble interferon‐α receptor molecules are present in body fluids

  1992cited by this paper
• A protein tyrosine kinase in the interferon alpha/beta signaling pathway.

  1992cited by this paper
• Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.

  1991cited by this paper
• The interferons. Mechanisms of action and clinical applications.

  1991cited by this paper
• Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.

  1990cited by this paper
• Disseminated or localized growth of a human B‐cell tumor (Daudi) in scid mice

  1990cited by this paper
• Stability of human interferon-ß1: oligomeric human interferon-ß1 is inactive but is reactivated by monomerization

  1989cited by this paper
• Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain.

  1989cited by this paper
• Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

  1989cited by this paper
• Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

  1989cited by this paper
• Isolation and characterization of a tumor necrosis factor binding protein from urine

  1989cited by this paper
• The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms.

  1989cited by this paper
• Interferons and their actions.

  1987cited by this paper
• The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone.

  1987cited by this paper
• Growth hormone receptor and serum binding protein: purification, cloning and expression

  1987cited by this paper
• A secreted form of the human interleukin 2 receptor encoded by an "anchor minus" cDNA.

  1986cited by this paper
• Modification of human leukocyte interferon pharmacology with a monoclonal antibody.

  1985cited by this paper
• Production of an epidermal growth factor receptor-related protein.

  1984cited by this paper
• Convenient assay for interferons

  1981cited by this paper

• Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy.

  2024cites this paper
• IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19

  2022cites this paper
• Which NK cell populations mark the high burden of CMV present in all HIV patients beginning ART in Indonesia?

  2022cites this paper
• Direct type I interferon signaling in hepatocytes controls malaria

  2022cites this paper
• Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment

  2021cites this paper
• Cytomegalovirus burden improves a predictive model identifying measures of vascular risk in renal transplant recipients and healthy adults

  2020cites this paper
• Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue

  2020cites this paper
• Structural integrity with functional plasticity: what type I IFN receptor polymorphisms reveal

  2020cites this paper
• Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation

  2020cites this paper
• Site-specific PEGylation of interferon beta-1b

  2020cites this paper
• Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model

  2019cites this paper
• Z-DNA and Z-RNA in human disease

  2019cites this paper
• Active and persistent cytomegalovirus infections affect T-cells in young adult HIV patients commencing ART

  2019cites this paper
• Active and Persistent Cytomegalovirus Infections Affect T Cells in Young Adult HIV Patients Commencing Antiretroviral Therapy

  2018cites this paper
• Alternative Pre-mRNA Splicing in Mammals and Teleost Fish: A Effective Strategy for the Regulation of Immune Responses Against Pathogen Infection

  2017cites this paper
• Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker

  2017cites this paper
• A Mathematical Model for the Macrophage Response to Respiratory Viral Infection in Normal and Asthmatic Conditions

  2017cites this paper
• Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis.

  2016influential citation
• The role of type I interferon in the immunobiology of chikungunya virus

  2015cites this paper
• Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis.

  2015cites this paper
• Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.

  2014cites this paper
• Development of a Mathematical Model to Understand, Design & Improve Oncolytic Virus Therapies

  2014cites this paper
• Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.

  2012cites this paper
• Effects of Interferons α/β on the Proliferation of Human Micro- and Macrovascular Endothelial Cells

  2011cites this paper
• Role of Differential Expression of Interferon Receptor Isoforms on the Response of Multiple Sclerosis Patients to Therapy with Interferon Beta

  2010cites this paper
• Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons

  2010cites this paper
• MxA protein assay for optimal monitoring of IFN‐β bioactivity in the treatment of MS patients

  2008cites this paper
• Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.

  2008cites this paper
• Decreased Type I Interferon Receptor-Soluble Isoform in Antiretroviral-Treated HIV-Positive Children

  2008cites this paper
• Two Interferons Alpha Influence Each Other During Their Interaction With the Extracellular Domain of Human Type I Interferon Receptor Subunit 2

  2008influential citation
• Two interferons alpha influence each other during their interaction with the extracellular domain of human type interferon receptor subunit 2.

  2007cites this paper
• Type I Interferon Receptors: Biochemistry and Biological Functions*

  2007cites this paper
• Type I Interferons in the Treatment of Pancreatic Cancer: Mechanisms of Action and Role of Related Receptors

  2007cites this paper
• IFN-β Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro

  2006cites this paper
• Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth.

  2006cites this paper
• Target-mediated drug disposition and dynamics.

  2006cites this paper
• Role of type I Interferons in the treatment of endocrine and non-endocrine cancers

  2006cites this paper
• IFN-B Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro

  2005cites this paper